Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -1.63% and +356.43%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?